Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?[ISRCTN63456799] by Chatterjee, Shyama & Van Marck, Eric
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Study protocol
Can somatostatin control acute bleeding from oesophageal varices 
in Schistosoma mansoni patients?[ISRCTN63456799]
Shyama Chatterjee* and Eric Van Marck
Address: Laboratory of Pathology, Faculty of Medicine, University of Antwerp, Universiteitsplein-1, 2610 Antwerp, Belgium
Email: Shyama Chatterjee* - Shyama.Chatterjee@ua.ac.be; Eric Van Marck - Eric.Van.Marck@uza.be
* Corresponding author    
Abstract
Background: Management of patients with bleeding oesophageal varices comprises of mainly
diagnostic endoscopy, sclerotherapy and band ligation. One of the major problems to do any of the
above is the active bleeding which makes any intervention difficult. The neuropeptide hormone
somatostatin administered exogenously has caused a reduction in portal hypertension and variceal
bleeding in patients suffering from liver cirrhosis. We believe that the symptomatic use of
somatostatin for variceal bleeding in Schistosoma mansoni infected subjects can reduce bleeding,
thereby alleviating the pathology caused by schistosomiasis.
Methods/design: We herein present a study protocol for establishing this neuropeptide as a
potential therapeutic agent in schistosomiasis. Adolescent subjects, age range varying from 12–17
years will be selected, based on several inclusion criteria, most important being infection with
Schistosoma mansoni with bleeding from oesophageal varices in the last 24 hours. One group of
schistosomiasis patients will be treated with somatostatin and praziquantel, the other with
propanolol and praziquantel. Survival graphs will be set up to correlate somatostatin administration
with survival time. A two part questionnaire will be set up to control treatment outcomes. The
pre-treatment part of the clinical questionnaire will identify inclusion criteria questions, the post-
treatment part of the questionnaire will identify treatment outcomes.
Discussion: We expect that the administration of somatostatin as a bolus followed by a 24 hour
long infusion, will stop bleeding immediately, delay rebleeding as compared to the control study
group and delay mortality in the somatostatin treated subjects.
Background
Complications due to severe schistosomiasis include
fibrosis, hepatomegaly, splenomegaly, haematemesis,
varices, portal hypertension, ascites formation and death
[1]. Complications resulting from hepatic fibrosis (such as
portal hypertension and variceal bleeding) are the princi-
pal cause of death in S. mansoni infected patients. In such
patients portal hypertension leads to the formation of
portal-systemic collaterals, specifically gastro-oesopha-
geal collaterals (varices). Bleeding of these oesophageal
varices can occur depending on the severity of fibrosis,
and can be fatal. Praziquantel, the most commonly used
anti-schistosomal drug, is effective against the worm
stages of the parasite, but has no activity against the
pathology (fibrosis) caused by the egg stages or the
variceal bleeding that can be fatal in its outcome. These
observations have stressed the need to combine praziqu-
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antel treatment with symptomatic treatment like with
somatostatin.
Somatostatin is emerging as the ideal vasoactive drug for
the control of variceal bleeding, and is as effective as scle-
rotherapy [2-4]. In a recent clinical trial, cirrhotic patients
with acute bleeding of oesophageal varices were treated
with infusion followed by bolus injections of somatosta-
tin just before sclerotherapy. Results showed fewer treat-
ment failures, fewer deaths or use of rescue therapy,
reduced blood transfusion and less frequent, active bleed-
ing. This drug also prevents recurrence and is free from
any major side effects even when administered over pro-
longed periods of time.
We have studied the potential role of somatostatin in
modulating  Schistosoma  caused morbidity. In endemic
regions, at any given time, only a fraction of infected
patients develop severe hepatic fibrosis. There may be a
direct correlation between the development of severe
fibrosis and the inability to generate required somatosta-
tin levels. Our ongoing research at the Laboratory of
Pathology give evidence to this fact, since somatostatin
levels in Senegalese patients with severe morbidity (hae-
matemesis, portal hypertension, variceal bleeding, ascites,
fibrosis) are significantly lower than that in patients with
no severe morbidity [5-10]. This effect indicates that
somatostatin could be administered exogenously for ther-
apeutic purposes in chronic schistosomiasis patients.
Complications linked to hepato-intestinal schistosomia-
sis are increasing in the area of Richard-Toll, Northern
Senegal. These cases are being identified at the local health
centre. However, considering the high prevalence of schis-
tosomiasis in this region, it is likely that the number of
severe cases is much higher. Clear guidelines for the man-
agement of such severe complications and criteria for
referral and surgery are required in this region. The estab-
lishment of an algorithm on how to treat these patients
and create the appropriate infrastructure is urgently
needed. The priority is how to take care of these patients
and more so what is the best way of doing this under local
conditions. One of the first steps is to critically evaluate
the Niamey-Belo-Horizonte ultrasound methodology in
patients with severe periportal fibrosis. Efficient manage-
ment of bleeding varices in the afflicted patients is imper-
ative.
Given the background that somatostatin is an ideal
vasoactive drug in the field of liver pathology, it is our
opinion that somatostatin will be more efficacious and
safe as compared to currently used beta blocker drugs like
propanolol, in the control of acute oesophageal variceal
bleeding due to Schistosoma mansoni infection. Moreover
using this neuropeptide may increase time to failure of
drug treatment, decrease incidences of early re-bleeding
(day 4, 8) and incidences of death during the follow up
period. Decreased frequencies of late rebleeding (days 30,
60, 90) may occur, all indicating the safety of using soma-
tostatin. Praziquantel cover would be given to all study
patients.
Study design
1. Selection of patients
Age and Morbidity criteria – Adolescent subjects, age
range varying from 12–17 years will be selected. The
inclusion criterion will be schistosomiasis patients with
bleeding from oesophageal varices in the last 24 hours. A
random selection will be made to form two groups, a
study group and a control group. Control of active infec-
tion will be done by means of CAA-strips on urine or
blood. Subjects will be asked to fill in an informed con-
sent form and the pre-treatment part of a questionnaire.
The inclusion criteria will be established fibrosis due to
schistosomiasis of clinical history, physical examination
and laboratory findings (and an examination compatible
with the presence of portal hypertension due to fibrosis).
Clinically active upper gastrointestinal bleeding (hae-
matemesis of fresh or semi fresh blood and/or melena
and/or haematochezia) with or without haemodynamic
instability (systolic blood pressure < 80 mm Hg and heart
rate > 120 bpm) will be selected. Subjects must be male or
non-pregnant, non-lactating female subjects. Females of
childbearing potential will have to utilize contraception
for the duration of the study. Written or verbal docu-
mented informed consent will be needed from all sub-
jects.
Exclusion criteria will include participation by subjects in
another investigational study within the last 14 days. Sub-
jects may not undergo treatment with endotherapy, i.e.
band ligation, sclerotherapy or other (balloon tampon-
ade). Treatment with somatostatin, vasopressin or their
analogues will also be a exclusion criteria. Subjects with
end stage liver disease with hepatorenal syndrome, diffuse
hepatocellular carcinoma, patent porto-systemic shunts,
known diagnosis of non-fibrotic portal hypertension,
severe cardiovascular diseases, i.e. acute myocardial inf-
arction and heart failure will be excluded. Concurrent use
of metoclopramide is also not advised.
Conduct of trial – Active bleeding episode (haematemesis,
haematochezia, melena) from a potential variceal source
should be confimed by a medical team (the ER physician,
the ICU physician, the investigator). Patients may be out-
patients or already hospitalised patients. Patients will be
randomised to either arm in a sequential manner. Ran-
domisation, and the start of study drug infusion if in
adjunctive therapy arm, should be accomplished as soonBMC Infectious Diseases 2004, 4:58 http://www.biomedcentral.com/1471-2334/4/58
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as possible following identification of a patient qualifying
for the study and following the conduct of pre-randomi-
sation study procedures.
Sample Size Criteria – Assuming a 80% chance of finding
a significant difference <0.05 between the two study
cohorts, the following statistics were established:
(A) If 99% of the untreated subjects and –
10% of somatostatin treated subjects bled -5 volunteers
per group were sufficient;
20% treated subjects bled – 7 volunteers per group were
required;
30% treated subjects bled-9 volunteers per group were
needed.
(B) If 90% of untreated subjects bled, and –
10% of somatostatin treated group bled – 7 volunteers in
each cohort were sufficient;
20% of somatostatin treated group bled – 9 volunteers in
each group were required;
30% of somatostatin treated group bled – 10 volunteers in
each group were needed.
(C) If 70% of untreated subjects bled, and:
10% of somatostatin treated group bled – 12 volunteers
per group were sufficient;
20% of somatostatin treated group bled – 18 volunteers
per group were required;
30% of somatostatin treated group bled – 28 volunteers
per group were needed.
In cirrhotic patients with bleeding oesophageal varices
somatostatin administration controls bleeding in more
than 80% of the treated patients. Based on this report, we
propose to start this pilot study with 10 subjects/group.
2. Treatment
Two groups of 10 schistosomiasis patients each will be
identified. Group (1) will be treated with Somatostatin
(3.5  µg/kg/hour; single bolus and i.v. infusion for 24
hours) + Praziquantel (40 mg/kg). For somatostatin treat-
ment the i.v. infusion will be started first; 3 mg somatosta-
tin will be dissolved in the 1 ml of saline provided. This
solution will be added to the saline transfusion unit and
administered to the patient for the next 12 hours. Once
finished the second packet of 3 mg somatostatin will be
used similarly for a second saline transfusion unit for the
remaining 12 hours. The bolus dose of 250 µg will be dis-
solved in the 1 ml of saline provided and administered
over 90 seconds soon after the start of the i.v. infusion.
Group (2) will be treated with Propanolol + Praziquantel.
3. Data analysis
Survival graphs will be set up to correlate somatostatin
administration with survival time.
The primary efficacy variable is the number of patients
meeting the failure of therapy definition during the infu-
sion period. Failure criteria are defined as death during
infusion, persistence of active bleeding (The haemody-
namic instability criteria points to the inability to achieve
and maintain a systolic blood pressure of 80 mm Hg OR
presence of a 20 mmHg drop in systolic blood pressure
from the highest post resuscitation value AND achieving a
heart rate of 120 bpm OR a 20 bpm increase from highest
post resuscitation value OR Inability to achieve and main-
tain a Hct of – 27% of Hb of – 9 g/dl despite blood trans-
fusion of 2 units or more.
The clinical criteria of active bleeding include hemateme-
sis (fresh or semi fresh blood), hematochezia, melena.
4. Control points
A two part questionnaire will be set up to control treat-
ment outcomes. The pre-treatment part of the clinical
questionnaire will identify inclusion criteria questions:
(1) When was the last haematemesis incidence?
(2) When did the present incident start?
The post-treatment part of the questionnaire will identify
treatment outcomes. The following questions will be
answered:
(1) What was the reaction to somatostatin infusion?
(2) When did bleeding stop after somatostatin infusion?
(3) GI disturbances: Is there abdominal pain, nausea,
diarrhea, after somatostatin infusion?
(4) Control of early rebleeding: Is there early rebleeding in
the 8 days following somatostatin administration?
(5) Control of late rebleeding: When is the next rebleed-
ing incident? Subjects will be followed up on a monthly
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(6) Control of mortality: Is there any difference in mortal-
ity time between the two groups.
(7) Control of fibrosis: Does ultrasonography detect anti-
fibrotic effect of somatostatin after treatment?
Discussion
It is expected that the administration of somatostatin as a
bolus followed by a 24 hour long infusion, will stop
bleeding immediately, delay rebleeding as compared to
the control study group and delay mortality in the soma-
tostatin treated subjects. Our protocol that is based on a
pilot study will help to establish the importance of soma-
tostatin in schistosomiasis.
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